JP2022541523A5 - - Google Patents
Info
- Publication number
- JP2022541523A5 JP2022541523A5 JP2022502958A JP2022502958A JP2022541523A5 JP 2022541523 A5 JP2022541523 A5 JP 2022541523A5 JP 2022502958 A JP2022502958 A JP 2022502958A JP 2022502958 A JP2022502958 A JP 2022502958A JP 2022541523 A5 JP2022541523 A5 JP 2022541523A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- pharmaceutical composition
- cell population
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878001P | 2019-07-24 | 2019-07-24 | |
| US62/878,001 | 2019-07-24 | ||
| GB1910605.3 | 2019-07-24 | ||
| GBGB1910605.3A GB201910605D0 (en) | 2019-07-24 | 2019-07-24 | Tumour infltracting lymphocyte therapy amd uses thereo |
| PCT/GB2020/051790 WO2021014174A1 (en) | 2019-07-24 | 2020-07-24 | Tumour infiltrating lymphocyte therapy and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541523A JP2022541523A (ja) | 2022-09-26 |
| JP2022541523A5 true JP2022541523A5 (https=) | 2023-07-26 |
Family
ID=67839864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502958A Pending JP2022541523A (ja) | 2019-07-24 | 2020-07-24 | 腫瘍内浸潤リンパ球療法及びその用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220378826A1 (https=) |
| EP (1) | EP4003372A1 (https=) |
| JP (1) | JP2022541523A (https=) |
| KR (1) | KR20220041839A (https=) |
| CN (1) | CN114174495A (https=) |
| AU (1) | AU2020316708A1 (https=) |
| BR (1) | BR112022001139A2 (https=) |
| CA (1) | CA3142913A1 (https=) |
| CL (1) | CL2022000152A1 (https=) |
| CO (1) | CO2021018066A2 (https=) |
| CR (1) | CR20220027A (https=) |
| EC (1) | ECSP22004616A (https=) |
| GB (1) | GB201910605D0 (https=) |
| IL (1) | IL289235A (https=) |
| MX (1) | MX2022000439A (https=) |
| PE (1) | PE20220258A1 (https=) |
| PH (1) | PH12022550146A1 (https=) |
| WO (1) | WO2021014174A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CN109536444B (zh) * | 2018-12-11 | 2022-06-28 | 吉林省拓华生物科技有限公司 | 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法 |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| MX2023011151A (es) * | 2021-03-23 | 2024-01-18 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Receptores de celulas t reactivas a antigenos. |
| EP4358978A4 (en) * | 2021-06-24 | 2025-04-16 | Instil Bio, Inc. | METHOD FOR ISOLATION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF |
| CN118962103B (zh) * | 2022-03-15 | 2025-07-22 | 上海君赛生物科技有限公司 | 肿瘤特异性免疫细胞标志物及其用途 |
| CN116162653A (zh) * | 2023-03-30 | 2023-05-26 | 湖北省农业科学院畜牧兽医研究所 | 靶向切除猪SlamF1基因编码区DNA的成对编辑位点、使用方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1867720A3 (en) * | 1994-12-02 | 2008-01-09 | Schering Corporation | Purified genes encoding mammalian cell surface antigens; proteins and antibodies |
| WO2002062999A2 (en) * | 2000-12-29 | 2002-08-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| DK2336167T3 (da) * | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| CN112851769A (zh) * | 2014-01-27 | 2021-05-28 | 分子模板公司 | 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽 |
| CA2940928C (en) * | 2014-04-07 | 2024-01-09 | Lokon Pharma Ab | Transmembrane cd154 proteins with oligomerization domain and medical uses thereof |
| WO2017179015A1 (en) * | 2016-04-15 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Compositions for the treatment of cancer |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| GB201801067D0 (en) * | 2018-01-23 | 2018-03-07 | Price Nicola Kaye | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
| CN113899903B (zh) * | 2020-07-06 | 2025-08-29 | 上海市免疫学研究所 | 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用 |
| CN116769729B (zh) * | 2023-06-05 | 2024-07-02 | 中国科学技术大学 | 靶向cd150的抗体或抗原结合片段及其应用 |
-
2019
- 2019-07-24 GB GBGB1910605.3A patent/GB201910605D0/en not_active Ceased
-
2020
- 2020-07-24 AU AU2020316708A patent/AU2020316708A1/en not_active Abandoned
- 2020-07-24 PE PE2022000015A patent/PE20220258A1/es unknown
- 2020-07-24 BR BR112022001139A patent/BR112022001139A2/pt not_active Application Discontinuation
- 2020-07-24 EP EP20751242.7A patent/EP4003372A1/en not_active Withdrawn
- 2020-07-24 KR KR1020227003064A patent/KR20220041839A/ko not_active Withdrawn
- 2020-07-24 MX MX2022000439A patent/MX2022000439A/es unknown
- 2020-07-24 JP JP2022502958A patent/JP2022541523A/ja active Pending
- 2020-07-24 CN CN202080048388.6A patent/CN114174495A/zh active Pending
- 2020-07-24 CA CA3142913A patent/CA3142913A1/en active Pending
- 2020-07-24 CR CR20220027A patent/CR20220027A/es unknown
- 2020-07-24 PH PH1/2022/550146A patent/PH12022550146A1/en unknown
- 2020-07-24 WO PCT/GB2020/051790 patent/WO2021014174A1/en not_active Ceased
-
2021
- 2021-12-21 IL IL289235A patent/IL289235A/en unknown
- 2021-12-29 CO CONC2021/0018066A patent/CO2021018066A2/es unknown
-
2022
- 2022-01-07 US US17/570,556 patent/US20220378826A1/en not_active Abandoned
- 2022-01-20 EC ECSENADI20224616A patent/ECSP22004616A/es unknown
- 2022-01-21 CL CL2022000152A patent/CL2022000152A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541523A5 (https=) | ||
| JP7653962B2 (ja) | 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法 | |
| US11338032B2 (en) | Methods of preparing anti-human papillomavirus antigen T cells | |
| Morrison et al. | Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells | |
| KR101391395B1 (ko) | 암환자의 면역치료를 위한 종양 반응성 ｔ－림프구의개선된 증식방법 | |
| Martin et al. | Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? | |
| CN111643524B (zh) | 从外周血中产生肿瘤反应性t细胞富集群的方法 | |
| Yang et al. | The effect of metformin on senescence of T lymphocytes | |
| Wang et al. | Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment | |
| Turlej et al. | Cross-talk between cancer and its cellular environment—A role in cancer progression | |
| Baharlou et al. | Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease | |
| KR20230150833A (ko) | 세포 배양 방법 | |
| Friedmann et al. | Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells | |
| CN109439627B (zh) | 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用 | |
| Ye et al. | Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC | |
| Lin et al. | CD215+ myeloid cells respond to interleukin 15 stimulation and promote tumor progression | |
| CN101346463B (zh) | 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法 | |
| Zheng et al. | FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8+ T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy | |
| Fang et al. | Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes | |
| Stroncek et al. | Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting | |
| Rezalotfi et al. | Gastrospheres as a model of gastric cancer stem cells skew th17/treg balance toward antitumor th17 cells | |
| De Silva et al. | 180P Photodynamic priming of pancreatic cancer: Enabling immunotherapy | |
| Janssen | Predicting clinical outcome in melanoma and breast cancer using blood and tumour-based immune biomarkers: a means to monitor anti-cancer immune responses | |
| Boutet et al. | Loss of the MLL3 tumor suppressor accelerates breast tumor onset via HIF1α-induced CCL2-mediated recruitment of CCR2+ regulatory T cells | |
| HK40088479A (en) | Methods of preparing anti-human papillomavirus antigen t cells |